BioCentury on BioBusiness,
Otsuka deal gives Lundbeck foothold in U.S. in psychiatry field
Related tables, figures and sidebars
Lundbeck psyched up
Monday, December 5, 2011
Lundbeck A/S's deal with Otsuka
Pharmaceutical Co. Ltd. for two late-stage programs is designed to take
the Danish pharma beyond replacing patent-related revenue losses, giving it
products to establish a foothold in the U.S. psychiatry market in advance of
launching its own depression drug.
In November, the companies
partnered to co-develop and co-commercialize two late-stage programs from
Otsuka and up to three programs from Lundbeck. The deal includes Otsuka's
once-monthly depot formulation of aripiprazole for maintenance treatment of
schizophrenia, which FDA accepted for review on Nov. 22. The PDUFA date is
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]